ZimVie, Zimmer Biomet's spine company spinoff, has cleared two international milestones, making its Mobi-C cervical disc replacement device more accessible in France and the United Kingdom, according to an April 3 press release sent to Becker's.
The French Republic has approved the Mobi-C cervical disc for reimbursement in both the public and private sectors, and the United Kingdom has awarded the device the highest quality rating by the Orthopaedic Data Evaluation Panel.
The U.K. rating designates strong evidence of performance and outcomes based on a generally higher number of patients, with all patients being subject to follow-up.
Physicians in France and the U.K. have been using Mobi-C in level one and level two applications since 2004.
"This reimbursement of the Mobi-C prosthesis is really excellent news. After almost 20 years of communicating the results of a French multi-center study, reimbursement for Mobi-C for both one- and two-level applications has been obtained," Dr. Thierry Dufour, spine neurosurgeon at Clinique Geoffroy Saint Hilaire in Paris, said in the release. "This decision was eagerly awaited by the French surgical community."